bit.bio Vienna, Austria
Sejla Salic-Hainzl received her training as a stem cell biologist in Sasha Mendjan's lab at IMBA. She gained extensive experience in drug discovery and CRISPR technologies by joining several early-stage biotech startups. At Signalomics, she worked on developing a quantum dot-based molecular imaging agent to enhance tumor detection. Following her time at Signalomics, Sejla contributed to the development of an antiviral drug candidate at Haplogen. At Myllia Biotechnology, she took on several leadership roles, and in 2020, she joined bit.bio Vienna, where she is now Vice President of R&D. At bit.bio, Sejla’s significant contributions include leading projects on disease modeling and CRISPR-ready ioCells, which hold immense potential for advancing drug target identification and validation.
UNLOCKING THE POWER OF DETERMINISTIC CELL PROGRAMMING IN BIOMEDICAL RESEARCH AND DRUG DISCOVERY
Thursday, July 11, 2024
12:00 PM – 1:00 PM CEST